key: cord-0013892-96ksvpij authors: Maruyama, Hiroki; Miyata, Kaori; Mikame, Mariko; Taguchi, Atsumi; Guili, Chu; Shimura, Masaru; Murayama, Kei; Inoue, Takeshi; Yamamoto, Saori; Sugimura, Koichiro; Tamita, Koichi; Kawasaki, Toshihiro; Kajihara, Jun; Onishi, Akifumi; Sugiyama, Hitoshi; Sakai, Teiko; Murata, Ichijiro; Oda, Takamasa; Toyoda, Shigeru; Hanawa, Kenichiro; Fujimura, Takeo; Ura, Shigehisa; Matsumura, Mimiko; Takano, Hideki; Yamashita, Satoshi; Matsukura, Gaku; Tazawa, Ryushi; Shiga, Tsuyoshi; Ebato, Mio; Satoh, Hiroshi; Ishii, Satoshi title: Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis date: 2019-02-06 journal: Genet Med DOI: 10.1038/s41436-019-0447-8 sha: 5d17f254d10e275ffe544794585baa8c5acfc983 doc_id: 13892 cord_uid: 96ksvpij nan 300 °C; source temperature, 150 °C; cone voltage, 55 V. The following multiple-reaction monitoring transitions were detected: m/z 786.4 to 282.3 (lyso-Gb3) and m/z 843.4 to 339.3 (Gly-lyso-Gb3). The concentration of plasma lyso-Gb3 was calculated from a linear calibration curve generated by plotting the ratio of the peak area of lyso-Gb3 to that of Glylyso-Gb3 versus the actual concentration of the lyso-Gb3 standard in control plasma. DNA and RNA were extracted from white blood cells using a QIAamp DNA Blood Mini Kit (Qiagen, Tokyo, Japan) and PAXgene Blood RNA Kit, respectively. Human GLA consists of seven exons; exons 1 and 7 were amplified from genomic DNA by polymerase chain reaction (PCR), and a fragment containing the full-length exons 2-6 and all exon-intron boundaries was obtained by reverse transcription (RT) PCR using total RNA. PCR and RT-PCR were performed under the conditions shown in Tables S1 and S2. Sequencing was performed as previously described. 14,18 When ordinary gene analysis revealed no mutations in females with a positive lyso-Gb3 screening result, we searched for long deletions using multiplex ligation-dependent probe amplification (MLPA) analysis and by assessing intronic mutations. Patients with negative lyso-Gb3 screening results and low α-Gal A activity were assessed for intronic mutations. MLPA was carried out following the manufacturer's instructions using SALSA MLPA P159-A5 GLA Probemix (MRC-Holland, Amsterdam, the Netherlands). PCR products were run on an ABI 3130xl Genetic Analyzer using GeneScan ROX 500 size standards (Applied Biosystems, Waltham, MA, USA). The data were normalized and analyzed using the Coffalyser NET software (MRC-Holland). PCR for introns was performed under the conditions shown in Tables S1 and S3. Ex7* g.10881-11301 5′-ACAAGTGCTTGATAGTTCTGA-3′ 5′-CAGGAAGTAGTAGTTGGCAA-3′ *Primer sets for ordinary gene analysis were previously described. 20 Entire introns were covered by the following primer sets; Ex1* for 2% of intron 1 from IVS1+1, † primer sets 35 for the remaining region of intron 1, and for introns 2 and 4, Ex3-4 for intron 3, Ex5-7 for introns 5 and 6. this study: Hiroshi Kawaguchi, Department of Nephrology Kojinkai Kimachi Hospital Misao Surgical Hospital Manabu Iwata, Hirosaki Stroke and Rehabilitation Center Department of Cardiology Showa General Hospital Iwata City Hospital Okayama Kyokuto Hospital Chuou Naika Clinic Ogaki Municipal Hospital Toyama Rosai Hospital Department of Cardiovascular Internal Medicine, Tosei General Hospital Soseikai General Hospital; Satoshi Sakai Mamoru Nobuhara, Department of Cardiology Yasushi Graduate School of Medicine Chisato Izumi, Department of Cardiology Faculty of Health Science Hiraka General Hospital Department of Cardiovascular Medicine Second Department of Internal Medicine Kosei General Hospital Fukaya Red Cross Hospital; Nobuya Fujita, Nagaoka Red Cross Hospital; Seiji Okubo, Department of Neurological Science, Graduate School of Medicine Department of Pediatrics Director Hokkaido Cardiovascular Hospital School of Health Sciences, Shinshu University; Hiroyuki Yabata Koshigaya Municipal Hospital Department of Pediatrics Orie Ichikawa, Department of Cardiology, National Hospital Organization Obama Municipal Hospital Division of Cardiovascular, Japan Community Health Care Organization Osaka Hospital Department of Nephrology Kitasaito Hospital Department of Nephrology, Mito Saiseikai General Hospital Shibagaki Dialysis Clinic Togoshi Shinkai Family Clinic Seitetsu Memorial Hospital Departments of Cerebrovascular Disease and Neurology, Hakujuji Hospital, Fukuoka; Ryota Tanaka Department of Neurology & Stroke Treatment Division of Nephrology Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital; Taku Nakagawa, Department of Pediatrics Kochi Prefectural Hata-Kenmin Hospital; Shin Hosino, Kasugai Municipal Hospital Department of Cardiology, Shizuoka Children's Hospital